China plans to inject Chinese medics with coronavirus vaccines by year-end to protect them to deal with any emergency situation, while 11 new confirmed COVID-19 cases were reported in the country with no deaths due to the virus, health officials said.
China's National Health Commission (NHC) on Tuesday said that 11 new confirmed COVID-19 cases were reported on Monday, of which four were imported.
The other seven new cases were domestically transmitted, the NHC said in a daily report, noting that six cases were reported in Heilongjiang Province bordering Russia and one in Guangdong Province.
The overall confirmed cases in China have reached 82,758 by Monday.
No death was reported on Monday. Altogether 4,632 people have died of the disease, it said.
Also, 37 new asymptomatic cases, including two from abroad, were reported on the mainland with 992 cases, including 180 from abroad, were still under medical observation.
However, Chinese health officials apprehend a second wave of the coronavirus attack especially from hundreds of Chinese nationals returning from abroad.
A Chinese health expert Zhang Wenhong said recently that China could be hit by a second wave of coronavirus cases in November this year as winter returns but by that time the country would be well prepared to deal with COVID-19.
Gao Fu, director of the Chinese Centre for Disease Control and Prevention (CDC) said in an emergency situation, some Chinese medics would be injected with coronavirus vaccines.
In accordance with how the epidemic develops, in case of emergency, some medical staff would be injected with a newly developed coronavirus vaccine, Gao said, noting that any medicines and vaccines have their own research and development cycles.
"I believe we could come up with vaccines with the joint efforts of everyone," he was quoted as saying by state-run Global Times.
China has approved three COVID-19 vaccine candidates for clinical trials.
An adenovirus vector vaccine, developed by Institute of Military Medicine under the Academy of Military Sciences, was the first to be approved to enter a clinical trial.
The first phase of the clinical trial was completed at the end of March, and the second phase started on April 12.
It is the first COVID-19 vaccine in the world that has entered the second phase of clinical trial, according to World Health Organisation (WHO), the Xinhua report said. Several countries, including China are speeding up coronavirus vaccine development to cut the time span to few months instead of several years.
Concerning the timetable for vaccine research and development, the director of the Chinese CDC said, "if you follow the normal procedure, the vaccine may not come out until the end of this year or early next year," noting that if the situation continues worsening, medics might be injected with the vaccines by the end of this year.
He also emphasised that this won't be used among normal people, the report said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
